Member Info for Yorkshirepragma

Https://www.biopharmadive.com/news/vertex-alpine-acquire-deal-kidney-igan-povetacicept/712886/

NB Chilton has good track record .

With positive further data set ,7 to 5 on.

Chair and CEO have likely gone for strategy disagreement . Growth to large company( always AS ambition) versus sale .

Funding has dictated this I suspect.

Await fireworks…

GLA

WAG, noted,

Taking the standard approach of an Exec, continuing the ‘ update thread’. We should see an informed update on commercial deals .after several months ‘ he’s very busy reported activity ‘( CC last session.

Should liven it up a bit.

GLA

Your, interesting point . Usually an embargo during any serious discussion.

We’ll see.

Almost.yes these great treatments are sadly a sig way off volume application. The very need to personalise is a barrier.

Volume drug application are here for some time . Enhancements such as 6000 are interesting to BP.

CC signalled clearly that talks are keeping the new CD busy.

Strange markets not seen this clearly?

Shorter GSM playing games no doubt .

GLA

I cool…

Yup and the busy( sorry very) commercial director needs to shine. As I see it..

-Could.be anytime

-Data’s good to date.

-BP always appreciates a high vol market.

- Dox has an accepted.record

Roumours abound..

Gla

Https://www.fiercepharma.com/special-reports/top-10-biopharma-ma-deals-2023

That’s board( personal)…when the pressures reset…do the needful.

I cool.

I’d say chances of a ‘ deal’ are now relatively high .

Evidence CEO rhetoric / very busy CD/ upbeat new USA style/ bird experience.

There again…

Https://www.biopharmadive.com/news/biotech-pharma-deals-merger-acquisitions-tracker/604262/

M& A ticking away,unpredictably . New team are presenting a better front, and no doubt will build on the ‘ upswing in interest ’.

Could happen tomorrow…or…

have emailed jonathan his**** gsa founder ( and a heavily publicised cancer charity fundraiser(hyp)), for an explanatory comment.

not holding my breath.

…

Brilliant science supporting a breakthrough chemo to benefit all one hopes.

If the ‘ it’s human to work here(sic)’ GSA Capital crowd are reading ,this is what you are NOT assisting with.

Well done…

New razzmatazz style….here. We go,let’s sell this tech.

BV . Offentimes it’ll come good!

I suspect deals shortly.

Dr Simon Bennett, Chief Business Officer, Avacta Therapeutics commented:

"Avacta is at a pivotal point, having recently announced clinical data that have already begun to generate interest from potential commercial partners. I am delighted to be joining at such an exciting point in the journey of the business, to help the team optimise the commercial opportunities of their technologies and assets."

CC …he’s very busy…

Ok

Merck associations exceed $20bn in recent years ( final vals).

A conjugate in association with Merck, would be a great advancement.

‘Data has supported an acceleration of groups commercial activites’ …ok